The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Proendotel     ethyl2-[8-chloro-3-(2- diethylaminoethyl)...

Synonyms: Cloricromen, Cloricromene, Cloricromeno, Cloricromenum, AD-6, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Cloricromene


High impact information on Cloricromene

  • The degree of staining for P-selectin, ICAM-1, nitrotyrosine, and PARS was markedly reduced in tissue sections obtained from LPS-recipient rats that had received cloricromene [1].
  • The degree of staining for iNOS, COX-2, nitrotyrosine and PARS were markedly reduced in tissue sections obtained from collagen-treated rats, which had received cloricromene [2].
  • 7. This study provides the first evidence that cloricromene, a coumarine derivative, attenuates the degree of chronic inflammation and tissue damage associated with collagen-induced arthritis in the rat [2].
  • 6. The incorporation of [3H]-acetate into [3H]-PAF induced by serum-treated zymosan in human PMNs was also inhibited concentration-dependently by cloricromene, with an IC50 of 105 microM [6].
  • 6. When monocyte adhesion was mediated by a large set of adhesive receptors, as obtained after treatment of HUVEC with either interleukin 1 beta (IL-1; 50 ng ml-1) or tumour necrosis factor-alpha (TNF; 100 u ml-1), the inhibitory effect of cloricromene was considerably reduced [7].

Chemical compound and disease context of Cloricromene


Biological context of Cloricromene


Anatomical context of Cloricromene


Associations of Cloricromene with other chemical compounds


Gene context of Cloricromene

  • Cloricromene treatment was associated with a minor body weight loss (p < 0.025) and significantly reduced tissue concentrations of MPO and TNF-alpha (p < 0.02, both) [20].
  • The macroscopic damage scores, colon wet weights, and tissue MIP-2 levels were significantly increased in untreated and in cloricromene-treated rats compared with controls [20].
  • 5. Both basal and chemoattractant-mediated monocyte adhesion was inhibited by cloricromene as it was by TS1/18, a monoclonal antibody (mAb) directed to beta 2 integrins; however, cytofluorimetric analysis showed that cloricromene was unable to modulate the expression of beta 2 integrins on the monocyte surface [7].
  • The pharmacokinetics of a lipophilic alkylamino acid (LAA) prodrug of cloricromene (AD6), name CLOR-C4, was studied in rat plasma and brain [21].
  • The effects of cloricromene on plasma endothelin-1 (ET-1) levels and on microcirculatory function in 9 patients with peripheral atherosclerotic arteriopathy (PAA) and in healthy control subjects were studied [22].

Analytical, diagnostic and therapeutic context of Cloricromene


  1. Effects of cloricromene, a coumarin derivative, on endotoxin-induced uveitis in Lewis rats. Bucolo, C., Cuzzocrea, S., Mazzon, E., Caputi, A.P. Invest. Ophthalmol. Vis. Sci. (2003) [Pubmed]
  2. Cloricromene, a coumarine derivative, protects against collagen-induced arthritis in Lewis rats. Cuzzocrea, S., Mazzon, E., Bevilaqua, C., Costantino, G., Britti, D., Mazzullo, G., De Sarro, A., Caputi, A.P. Br. J. Pharmacol. (2000) [Pubmed]
  3. Cloricromene reduces myocardial infarct size in rabbits when administered during the early reperfusion period. Zvara, D.A., Galaska, H.J., Castellano, V.P., Vinten-Johansen, J., Royster, R.L., Williams, M.W., Murphy, B.A., Kim, E.J. Anesth. Analg. (1997) [Pubmed]
  4. Cloricromene, a coumarine derivative, reduced the development of periodontitis in rats. Muià, C., Mazzon, E., Zito, D., Maiere, D., Britti, D., Crisafulli, C., Oteri, G., Cordasco, G., Cuzzocrea, S. Naunyn Schmiedebergs Arch. Pharmacol. (2006) [Pubmed]
  5. Cloricromene in endotoxemia: role of NF-kappaB. Ianaro, A., Maffia, P., Grassia, G., Di Meglio, P., Sorrentino, R., di Villa Bianca, R., Di Rosa, M., Ialenti, A. Naunyn Schmiedebergs Arch. Pharmacol. (2004) [Pubmed]
  6. Inhibition of PAF synthesis by stimulated human polymorphonuclear leucocytes with cloricromene, an inhibitor of phospholipase A2 activation. Ribaldi, E., Mezzasoma, A.M., Francescangeli, E., Prosdocimi, M., Nenci, G.G., Goracci, G., Gresele, P. Br. J. Pharmacol. (1996) [Pubmed]
  7. Inhibition of human monocyte adhesion to endothelial cells by the coumarin derivative, cloricromene. Tranchina, S., Bernasconi, S., Dejana, E., Del Maschio, A. Br. J. Pharmacol. (1994) [Pubmed]
  8. Multiple actions of the coumarine derivative cloricromene and its protective effects on ischemic brain injury. Calapai, G., Squadrito, F., Rizzo, A., Marciano, M.C., Campo, G.M., Caputi, A.P. Naunyn Schmiedebergs Arch. Pharmacol. (1995) [Pubmed]
  9. Dissociation of the anti-ischaemic effects of cloricromene from its anti-platelet activity. Lidbury, P.S., Cirillo, R., Vane, J.R. Br. J. Pharmacol. (1993) [Pubmed]
  10. Ultrastructural modifications of the platelet plasma membrane in vascular diseases and the effect of a carbochromen derivative as studied by freeze-fracture and computer measurement. Bianciardi, G., Vittoria, A., Toti, P., Franchi, M., Martelli, G., Di Perri, T., Weber, G. Atherosclerosis (1986) [Pubmed]
  11. Participation of tumour necrosis factor and nitric oxide in the mediation of vascular dysfunction in splanchnic artery occlusion shock. Squadrito, F., Altavilla, D., Canale, P., Ioculano, M., Campo, G.M., Ammendolia, L., Ferlito, M., Zingarelli, B., Squadrito, G., Saitta, A. Br. J. Pharmacol. (1994) [Pubmed]
  12. Cloricromene, a coumarine derivative, protects against lethal endotoxin shock in rats. Squadrito, F., Altavilla, D., Campo, G.M., Calapai, G., Ioculano, M., Zingarelli, B., Saitta, A., Prosdocimi, M., Caputi, A.P. Eur. J. Pharmacol. (1992) [Pubmed]
  13. In vitro inhibition of human polymorphonuclear cell function by cloricromene. Bertocchi, F., Breviario, F., Proserpio, P., Wang, J.M., Ghezzi, P., Travagli, R.A., Prosdocimi, M., Dejana, E. Naunyn Schmiedebergs Arch. Pharmacol. (1989) [Pubmed]
  14. Polymorphonuclear leukocyte-dependent modulation of platelet function: effect of cloricromene. Zatta, A., Prosdocimi, M., Bazzoni, G., Dejana, E., Del Maschio, A. Eur. J. Pharmacol. (1991) [Pubmed]
  15. Cloricromene, a semi-synthetic coumarin derivative, inhibits tumor necrosis factor-alpha production at a pre-transcriptional level. Corsini, E., Lucchi, L., Binaglia, M., Viviani, B., Bevilacqua, C., Monastra, G., Marinovich, M., Galli, C.L. Eur. J. Pharmacol. (2001) [Pubmed]
  16. Determination of the coumarin derivative cloricromene acid in rabbit plasma and platelets. Mariot, R., Zangirolami, L., Bellato, P., Chen, S., Pieraccini, G., Moneti, G. J. Chromatogr. (1992) [Pubmed]
  17. Eudragit RL100 nanoparticle system for the ophthalmic delivery of cloricromene. Bucolo, C., Maltese, A., Maugeri, F., Busà, B., Puglisi, G., Pignatello, R. J. Pharm. Pharmacol. (2004) [Pubmed]
  18. Efficacy of tumor necrosis factor alpha and eicosanoid inhibitors in experimental models of neonatal sepsis. Mancuso, G., Cusumano, V., Cook, J.A., Smith, E., Squadrito, F., Blandino, G., Teti, G. FEMS Immunol. Med. Microbiol. (1994) [Pubmed]
  19. Reduction of myocardial damage by cloricromene during ischemia-reperfusion in the rabbit. Milei, J., Llesuy, S., Ferreira, R., Grana, D., Prosdocimi, M., Boveris, A. Cardioscience. (1992) [Pubmed]
  20. A protective effect of the synthetic coumarine derivative Cloricromene against DNB-colitis in the rat. Fries, W., Mazzon, E., Sturiale, S., Giofré, M.R., Lo Presti, M.A., Cuzzocrea, S., Campo, G.M., Caputi, A.P., Longo, G., Sturniolo, G.C. Life Sci. (2004) [Pubmed]
  21. Enhancement of availability of cloricromene at brain level by a lipophilic prodrug. Pignatello, R., Maltese, A., Maugeri, F., Bucolo, C. J. Pharm. Pharmacol. (2006) [Pubmed]
  22. Effects of cloricromene on the levels of endothelin and on the microcirculatory function in peripheral atherosclerotic arteriopathies. Saitta, A., Bonaiuto, M., Giordano, G., Saitta, M.N., Castaldo, M., Cinquegrani, M., Squadrito, G., Canale, P., Altavilla, D., Campo, G.M., Caputi, A.P., Squadrito, F. Pharmacology (1996) [Pubmed]
  23. Effect of cloricromene on intermittent claudication. A randomized, double-blind, placebo-controlled trial in patients treated with aspirin: effect on claudication distance and quality of life. CRAMPS Investigator Group. Cloricromene Randomized Arteriopathy Multicenter Prospective Study. Gresele, P., Migliacci, R., Di Sante, G., Nenci, G.G. Vascular medicine (London, England) (2000) [Pubmed]
  24. The effect of cloricromene, a coumarine derivative, on leukocyte accumulation, myocardial necrosis and TNF-alpha production in myocardial ischaemia-reperfusion injury. Squadrito, F., Altavilla, D., Zingarelli, B., Ioculano, M., Calapai, G., Campo, G.M., Miceli, A., Prosdocimi, M., Caputi, A.P. Life Sci. (1993) [Pubmed]
WikiGenes - Universities